BACKGROUND: Immunotherapeutic cancer protocols often rely on the ability to promote proliferative expansion of tumor-specific T-cell, but the influence of cancer on in vivo T-cell expansion remains largely undefined. METHODS: The ability of control and B16F10 melanoma-bearing C57BL/6 mice to expand lymphocytic choriomeningitis virus antigen-specific T-cell populations in response to acute viral infection was compared by using flow cytometric assays of splenocytes. RESULTS: The ability to expand virus-specific CD8+ and CD4+ T-cells was globally and markedly suppressed in tumor-bearing mice. Expanded cytotoxic T lymphocytes (CTLs) retained in vivo and in vitro functionality, suggesting that melanoma growth did not induce T-cell anergy. The magnitude of suppressed proliferative expansion was proportional to the extent of tumor burden. Melanoma-induced suppression of CTL expansion was correlated with upregulated apoptotic activity and hampered the induction of memory precursor effector cells. Adoptive transfer of resting LCMV antigen-specific T-cells before or after tumor establishment demonstrated that a critical period of in vivo exposure of resting T-cells to growing melanoma was responsible for the induction of suppressed expansion. This suppression was durable; surgical resection of melanoma after in vivo exposure to resting T-cells but before antigenic stimulation did not restore full expansion. CONCLUSIONS: These data suggest that growing melanoma tumors exert a global, antigen-independent influence on resting T-cells that fundamentally reprograms their ability to undergo proliferative expansion in response to subsequent antigenic stimulation. This finding may have direct implications for T-cell-based immunotherapeutic strategies.
BACKGROUND: Immunotherapeutic cancer protocols often rely on the ability to promote proliferative expansion of tumor-specific T-cell, but the influence of cancer on in vivo T-cell expansion remains largely undefined. METHODS: The ability of control and B16F10 melanoma-bearing C57BL/6 mice to expand lymphocytic choriomeningitis virus antigen-specific T-cell populations in response to acute viral infection was compared by using flow cytometric assays of splenocytes. RESULTS: The ability to expand virus-specific CD8+ and CD4+ T-cells was globally and markedly suppressed in tumor-bearing mice. Expanded cytotoxic T lymphocytes (CTLs) retained in vivo and in vitro functionality, suggesting that melanoma growth did not induce T-cell anergy. The magnitude of suppressed proliferative expansion was proportional to the extent of tumor burden. Melanoma-induced suppression of CTL expansion was correlated with upregulated apoptotic activity and hampered the induction of memory precursor effector cells. Adoptive transfer of resting LCMV antigen-specific T-cells before or after tumor establishment demonstrated that a critical period of in vivo exposure of resting T-cells to growing melanoma was responsible for the induction of suppressed expansion. This suppression was durable; surgical resection of melanoma after in vivo exposure to resting T-cells but before antigenic stimulation did not restore full expansion. CONCLUSIONS: These data suggest that growing melanoma tumors exert a global, antigen-independent influence on resting T-cells that fundamentally reprograms their ability to undergo proliferative expansion in response to subsequent antigenic stimulation. This finding may have direct implications for T-cell-based immunotherapeutic strategies.
Authors: D C Lockhart; A K Chan; S Mak; H G Joo; H A Daust; A Carritte; C C Douville; P S Goedegebuure; T J Eberlein Journal: Surgery Date: 2001-06 Impact factor: 3.982
Authors: Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley Journal: Nat Rev Cancer Date: 2008-04 Impact factor: 60.716
Authors: Francesco M Marincola; Ena Wang; Meenhard Herlyn; Barbara Seliger; Soldano Ferrone Journal: Trends Immunol Date: 2003-06 Impact factor: 16.687
Authors: Erika A Danna; Pratima Sinha; Mileka Gilbert; Virginia K Clements; Beth A Pulaski; Suzanne Ostrand-Rosenberg Journal: Cancer Res Date: 2004-03-15 Impact factor: 12.701
Authors: Susan M Kaech; Joyce T Tan; E John Wherry; Bogumila T Konieczny; Charles D Surh; Rafi Ahmed Journal: Nat Immunol Date: 2003-11-16 Impact factor: 25.606
Authors: Andrew J Russ; Kyle Xu; Lucy Wentworth; Sheeba Alam; Justin V Meyers; Michael D Macklin; Alexander L Rakhmilevich; Victoria Rajamanickam; M Suresh; Clifford S Cho Journal: Cell Immunol Date: 2011-06-17 Impact factor: 4.868
Authors: Amanda Contreras; Siddhartha Sen; Andrew J Tatar; David A Mahvi; Justin V Meyers; Prakrithi Srinand; Marulasiddappa Suresh; Clifford S Cho Journal: Cancer Immunol Immunother Date: 2016-03-24 Impact factor: 6.968
Authors: David A Mahvi; Justin V Meyers; Andrew J Tatar; Amanda Contreras; Marulasiddappa Suresh; Glen E Leverson; Siddhartha Sen; Clifford S Cho Journal: J Immunother Date: 2015 Feb-Mar Impact factor: 4.456
Authors: Lucy Wentworth; Justin V Meyers; Sheeba Alam; Andrew J Russ; M Suresh; Clifford S Cho Journal: Cancer Immunol Immunother Date: 2012-08-04 Impact factor: 6.968
Authors: Edmund K Moon; Liang-Chuan Wang; Douglas V Dolfi; Caleph B Wilson; Raghuveer Ranganathan; Jing Sun; Veena Kapoor; John Scholler; Ellen Puré; Michael C Milone; Carl H June; James L Riley; E John Wherry; Steven M Albelda Journal: Clin Cancer Res Date: 2014-06-11 Impact factor: 12.531
Authors: Amanda Contreras; Megan V Beems; Andrew J Tatar; Siddhartha Sen; Prakrithi Srinand; M Suresh; Tahra K Luther; Clifford S Cho Journal: J Immunother Cancer Date: 2018-05-29 Impact factor: 13.751
Authors: Shibin Qu; Tejaswi Worlikar; Amy E Felsted; Anutosh Ganguly; Megan V Beems; Ryan Hubbard; Ashley L Pepple; Alicia A Kevelin; Hannah Garavaglia; Joe Dib; Mariam Toma; Hai Huang; Allan Tsung; Zhen Xu; Clifford Suhyun Cho Journal: J Immunother Cancer Date: 2020-01 Impact factor: 13.751